DFTX: Meets Efficacy Endpoints
Definium Therapeutics announces topline results from its Phase 3 Emerge study, meeting primary and key secondary efficacy endpoints for DT120 in major depressive disorder
Definium Therapeutics Announces Topline Results From Its Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet In Major Depressive Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints